Baker BROS. Advisors LP Purchases 1,787,244 Shares of Roivant Sciences Ltd. $ROIV

Baker BROS. Advisors LP lifted its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 47.4% during the 4th quarter, Holdings Channel reports. The firm owned 5,555,017 shares of the company’s stock after acquiring an additional 1,787,244 shares during the period. Roivant Sciences comprises about 0.7% of Baker BROS. Advisors LP’s holdings, making the stock its 21st biggest holding. Baker BROS. Advisors LP’s holdings in Roivant Sciences were worth $120,544,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in ROIV. UBS Group AG boosted its holdings in Roivant Sciences by 570.0% in the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after acquiring an additional 15,645,836 shares in the last quarter. Morgan Stanley boosted its holdings in Roivant Sciences by 31.7% in the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after acquiring an additional 14,036,696 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Roivant Sciences by 365.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after acquiring an additional 8,621,567 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in Roivant Sciences by 11,507.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock valued at $150,535,000 after acquiring an additional 6,877,348 shares in the last quarter. Finally, Norges Bank bought a new stake in Roivant Sciences in the fourth quarter valued at $112,750,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Trading Up 2.6%

Shares of Roivant Sciences stock opened at $31.20 on Thursday. The firm has a market capitalization of $22.44 billion, a P/E ratio of -52.00 and a beta of 1.13. The business has a fifty day simple moving average of $29.10 and a two-hundred day simple moving average of $26.22. Roivant Sciences Ltd. has a 12 month low of $10.70 and a 12 month high of $32.79.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of ($0.29) by $0.57. The business had revenue of $2.52 million during the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same quarter last year, the firm posted ($0.29) earnings per share. Analysts predict that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ROIV shares. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a report on Thursday, May 21st. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Guggenheim lifted their price target on shares of Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Finally, Weiss Ratings lowered Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $33.59.

Insider Transactions at Roivant Sciences

In other news, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $30.27, for a total value of $6,054,000.00. Following the completion of the transaction, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at $48,827,417.01. The trade was a 11.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Jennifer Humes sold 13,538 shares of Roivant Sciences stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total value of $384,073.06. Following the completion of the transaction, the chief accounting officer directly owned 84,191 shares of the company’s stock, valued at approximately $2,388,498.67. This represents a 13.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 703,312 shares of company stock valued at $20,805,883 in the last quarter. 10.80% of the stock is owned by insiders.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.